Songül Tezcan1, Fikret Vehbi İzzettin1, Mesut Sancar1, Nazım Serdar Turhal2, Perran Fulden Yumuk3. 1. Department of Clinical Pharmacy, Faculty of Pharmacy, The University of Marmara, Istanbul, Turkey. 2. Department of Internal Medicine, Division of Medical Oncology, Anadolu Medical Center, Kocaeli, Turkey. 3. Department of Internal Medicine, Division of Medical Oncology, Marmara University Medical School, Istanbul, Turkey.
Abstract
OBJECTIVE: To determine and evaluate the pharmaceutical care needs and quality of life of patients with colorectal cancer. METHODS: 36 Patients with colorectal cancer eligible for chemotherapy after surgery were included in the study. The patients were followed up during 3 courses of chemotherapy and individual pharmaceutical care plans were developed. The quality of life of patients was evaluated before and after the third course of chemotherapy. RESULTS: The incidence of drug-related problems (DRPs) in chemotherapy-treated patients was reduced in the 3rd course as compared with 1st course (63.9% vs 75%, respectively; n=36; p>0.05). The clinical oncology pharmacist gave 147 recommendations to patients, which were followed in 98% (n=144) of cases. 91.7% (n=132) of the recommendations of clinical oncology pharmacists solved the drug-related problems; however, the remaining 8.3% (n=12) did not solve the problems and the patients were referred to a doctor for further investigations. The symptom-related quality of life of patients related to anaemia, diarrhoea and neurotoxicity was reduced after the third course of chemotherapy (p<0.05). CONCLUSIONS: The pharmaceutical care provided by the clinical oncology pharmacist has an important role in the identification and resolution of DRPs. Evaluation of symptom-related quality of life is important for the monitoring of patients receiving chemotherapy.
OBJECTIVE: To determine and evaluate the pharmaceutical care needs and quality of life of patients with colorectal cancer. METHODS: 36 Patients with colorectal cancer eligible for chemotherapy after surgery were included in the study. The patients were followed up during 3 courses of chemotherapy and individual pharmaceutical care plans were developed. The quality of life of patients was evaluated before and after the third course of chemotherapy. RESULTS: The incidence of drug-related problems (DRPs) in chemotherapy-treated patients was reduced in the 3rd course as compared with 1st course (63.9% vs 75%, respectively; n=36; p>0.05). The clinical oncology pharmacist gave 147 recommendations to patients, which were followed in 98% (n=144) of cases. 91.7% (n=132) of the recommendations of clinical oncology pharmacists solved the drug-related problems; however, the remaining 8.3% (n=12) did not solve the problems and the patients were referred to a doctor for further investigations. The symptom-related quality of life of patients related to anaemia, diarrhoea and neurotoxicity was reduced after the third course of chemotherapy (p<0.05). CONCLUSIONS: The pharmaceutical care provided by the clinical oncology pharmacist has an important role in the identification and resolution of DRPs. Evaluation of symptom-related quality of life is important for the monitoring of patients receiving chemotherapy.
Entities:
Keywords:
Colorectal cancer; clinical oncology pharmacist; drug related problems; pharmaceutical care; quality of life
Authors: Axel Grothey; Daniel A Nikcevich; Jeff A Sloan; John W Kugler; Peter T Silberstein; Todor Dentchev; Donald B Wender; Paul J Novotny; Umesh Chitaley; Steven R Alberts; Charles L Loprinzi Journal: J Clin Oncol Date: 2010-12-28 Impact factor: 44.544
Authors: Saul N Weingart; Angela Cleary; Andrew Seger; Terry K Eng; Mark Saadeh; Anne Gross; Lawrence N Shulman Journal: Jt Comm J Qual Patient Saf Date: 2007-12
Authors: Helena Harder; Valerie M Shilling; Shirley F May; David Cella; Peter Schmid; Lesley J Fallowfield Journal: Breast Cancer Res Treat Date: 2020-07-27 Impact factor: 4.872